{"id":"placebo-asenapine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"5-10","effect":"Oral hypoesthesia/paresthesia"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asenapine acts as an antagonist at multiple dopamine receptors (D2, D3) and serotonin receptors (5-HT2A, 5-HT7), with particular affinity for D2 and 5-HT2A. This dual antagonism is characteristic of atypical antipsychotics and helps reduce both positive symptoms (hallucinations, delusions) and negative symptoms (withdrawal, apathy) of psychotic disorders while potentially having a lower risk of extrapyramidal side effects compared to typical antipsychotics.","oneSentence":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:39.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"}]},"trialDetails":[{"nctId":"NCT00156104","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-01","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT00159796","phase":"PHASE3","title":"3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-14","conditions":"Bipolar Disorder","enrollment":489},{"nctId":"NCT00159744","phase":"PHASE3","title":"3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-30","conditions":"Bipolar Disorder","enrollment":488},{"nctId":"NCT00156117","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-12","conditions":"Schizophrenia","enrollment":417},{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT00151424","phase":"PHASE3","title":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-15","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT01098110","phase":"PHASE3","title":"6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-05-25","conditions":"Schizophrenia","enrollment":532},{"nctId":"NCT01244815","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder, Pediatric","enrollment":404},{"nctId":"NCT01617187","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-04","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00764478","phase":"PHASE3","title":"Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-04-06","conditions":"Bipolar 1 Disorder","enrollment":367},{"nctId":"NCT01142596","phase":"PHASE3","title":"Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-05-25","conditions":"Schizophrenia","enrollment":201},{"nctId":"NCT01349907","phase":"PHASE3","title":"Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder","enrollment":322},{"nctId":"NCT01190254","phase":"PHASE3","title":"Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-28","conditions":"Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated","enrollment":306},{"nctId":"NCT00145470","phase":"PHASE3","title":"12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-06-02","conditions":"Bipolar Disorder","enrollment":326},{"nctId":"NCT00156091","phase":"PHASE3","title":"Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Schizophrenia","enrollment":260},{"nctId":"NCT00212771","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":440},{"nctId":"NCT00150176","phase":"PHASE3","title":"To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Schizophrenia","enrollment":831},{"nctId":"NCT00145509","phase":"PHASE3","title":"40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Bipolar Disorder","enrollment":77},{"nctId":"NCT00156065","phase":"PHASE3","title":"Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Schizophrenia","enrollment":187},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT02876900","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.","status":"COMPLETED","sponsor":"Noven Pharmaceuticals, Inc.","startDate":"2016-08","conditions":"Schizophrenia","enrollment":617},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT01807741","phase":"PHASE2","title":"Asenapine for Bipolar Depression","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2013-09","conditions":"Bipolar Depression","enrollment":51},{"nctId":"NCT01400113","phase":"PHASE4","title":"Treating Acutely Agitated Patients With Asenapine Sublingual Tablets","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2012-04","conditions":"Agitation","enrollment":120},{"nctId":"NCT01396291","phase":"PHASE3","title":"Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Bipolar 1 Disorder","enrollment":561},{"nctId":"NCT01670019","phase":"PHASE4","title":"Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-10","conditions":"Major Depressive Disorder Without Psychotic Features","enrollment":46},{"nctId":"NCT01395992","phase":"PHASE3","title":"Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-04","conditions":"Bipolar I Disorder","enrollment":165},{"nctId":"NCT01617200","phase":"PHASE3","title":"Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-12","conditions":"Schizophrenia","enrollment":105},{"nctId":"NCT01684657","phase":"PHASE3","title":"A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering","status":"SUSPENDED","sponsor":"University of California, Irvine","startDate":"2012-09","conditions":"Stuttering","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Asenapine","genericName":"Placebo Asenapine","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}